Ignite Creation Date:
2025-12-25 @ 4:26 AM
Ignite Modification Date:
2025-12-26 @ 3:30 AM
Study NCT ID:
NCT05623020
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2022-10-26
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Sponsor:
Pfizer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-11-10
Start Date Type:
ACTUAL
Primary Completion Date:
2028-03-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-11-29
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-26
First Submit QC Date:
None
Study First Post Date:
2022-11-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-11
Last Update Post Date:
2025-12-17
Last Update Post Date Type:
ESTIMATED